| Texto completo | |
| Autor(es): Mostrar menos - |
de Lima Junior, Edson Alves
;
Teixeira, Alexandre Abilio de Souza
;
Silveira, Loreana Sanches
;
Jove, Queralt
;
Ladron, Natalia alvarez
;
Pereira, Marcelo G.
;
Lopez-Soriano, Francisco Javier
;
Argiles, Josep M.
;
Brum, Patricia Chakur
;
Busquets, Silvia
;
Rosa Neto, Jose Cesar
Número total de Autores: 11
|
| Tipo de documento: | Artigo Científico |
| Fonte: | FRONTIERS IN ONCOLOGY; v. 13, p. 8-pg., 2024-01-03. |
| Resumo | |
Background Even though doxorubicin (DOX) chemotherapy promotes intense muscle wasting, this drug is still widely used in clinical practice due to its remarkable efficiency in managing cancer. On the other hand, intense muscle loss during the oncological treatment is considered a bad prognosis for the disease's evolution and the patient's quality of life. In this sense, strategies that can counteract the muscle wasting induced by DOX are essential. In this study, we evaluated the effectiveness of formoterol (FOR), a beta 2-adrenoceptor agonist, in managing muscle wasting caused by DOX.Methods and results To evaluate the effect of FOR on DOX-induced muscle wasting, mice were treated with DOX (2.5 mg/kg b.w., i.p. administration, twice a week), associated or not to FOR treatment (1 mg/kg b.w., s.c. administration, daily). Control mice received vehicle solution. A combination of FOR treatment with DOX protected against the loss of body weight (p<0.05), muscle mass (p<0.001), and grip force (p<0.001) promoted by chemotherapy. FOR also attenuated muscle wasting (p<0.01) in tumor-bearing mice on chemotherapy. The potential mechanism by which FOR prevented further DOX-induced muscle wasting occurred by regulating Akt/FoxO3a signaling and gene expression of atrogenes in skeletal muscle.Conclusions Collectively, our results suggest that FOR can be used as a pharmacological strategy for managing muscle wasting induced by DOX. This study provides new insights into the potential therapeutic use of FOR to improve the overall wellbeing of cancer patients undergoing DOX chemotherapy. (AU) | |
| Processo FAPESP: | 13/09367-4 - Efeitos metabólicos da doxorrubicina no músculo esquelético e tecido adiposo: possível papel adjuvante do treinamento físico e metformina |
| Beneficiário: | José Cesar Rosa Neto |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |
| Processo FAPESP: | 19/09854-9 - O efeito da doxorrubicina sobre o tecido adiposo: elucidando o papel da família dos PPARs |
| Beneficiário: | José Cesar Rosa Neto |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |
| Processo FAPESP: | 19/01244-7 - Manejo farmacológico e não farmacológico da perda muscular |
| Beneficiário: | Edson Alves de Lima Junior |
| Modalidade de apoio: | Bolsas no Exterior - Estágio de Pesquisa - Doutorado |
| Processo FAPESP: | 15/17068-2 - Efeito do treinamento físico aeróbio associado ao tratamento quimioterápico com doxorrubicina em camundongos com carcinoma de pulmão Lewis (LLC). Papel da adiponectina no músculo estriado esquelético e no tumor. |
| Beneficiário: | Edson Alves de Lima Junior |
| Modalidade de apoio: | Bolsas no Brasil - Doutorado |